Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Up 3,557.9% in February

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 4,865,346 shares, a growth of 3,557.9% from the February 12th total of 133,008 shares. Currently, 120.2% of the company’s stock are sold short. Based on an average trading volume of 40,722,544 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 40,722,544 shares, the short-interest ratio is presently 0.1 days. Currently, 120.2% of the company’s stock are sold short.

Avalon GloboCare Stock Performance

NASDAQ:ALBT opened at $0.84 on Wednesday. The stock has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.59. The firm has a market capitalization of $3.59 million, a PE ratio of -0.24 and a beta of -0.23. Avalon GloboCare has a 52-week low of $0.42 and a 52-week high of $7.89.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Avalon GloboCare has a consensus rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.